QDx Pathology Services, an unbiased anatomical, molecular, and medical pathology laboratory serving medical professionals and services all through the U.S., is working with Proscia, a supplier of digital and computational pathology options, to innovate its follow. The laboratory has deployed Proscia’s software program to allow its pathologists to work quicker and extra confidently.
Digital pathology is modernizing the microscope-based normal, driving a shift to high-resolution photos containing over 1 billion pixels telling the story of a affected person’s illness. Accelerated by a rising proof, laboratories are adopting digital pathology to boost routine operations, enhance decision-making, and lay the muse for unlocking new insights with AI.
“At QDx Pathology Companies, we’re dedicated to advancing the usual of excellence in pathology,” stated Pierre Mouawad, VP of Laboratory Operations. “Proscia’s software program makes it simpler for our pathologists to do their greatest work, empowering them to optimize for velocity and precision. We have now already seen an affect from our determination to undertake this state-of-the-art answer.”
With its intuitive person expertise, sturdy performance, and scalability, Proscia’s software program allows pathologists to drive productiveness and confidence good points of their routine workflows. This consists of streamlining collaboration, which helps them to faucet right into a broader pool of experience. QDx Pathology Companies plans to keep up its place of innovation by leveraging the answer’s world-class interoperability with AI purposes developed by Proscia, Proscia’s prospects, and the Proscia Prepared companions.
“It’s inspiring to look at QDx Pathology Companies take the primary steps on its digital pathology journey,” stated David West, Proscia’s CEO. “The staff understands all that it takes to achieve success, together with a tradition of innovation, dedication to its pathologists and people impacted by their work, and a powerful software program basis. We have now full confidence that it’s going to notice the complete promise of digital pathology.”
Immediately’s information is the newest in a collection of latest bulletins from Proscia. Final month, the corporate acquired FDA 510(k) clearance for its Concentriq AP-Dx answer. It additionally launched the Proscia Ready partner alliance to assist life sciences organizations and diagnostic laboratories speed up the scaled adoption of digital pathology with confidence.
To be taught extra about Proscia’s software program and see a demo, go to sales space 200 throughout the upcoming United States and Canadian Academy of Pathology (USCAP) 113th Annual Assembly.
Digital pathology is modernizing the microscope-based normal, driving a shift to high-resolution photos containing over 1 billion pixels telling the story of a affected person’s illness. Accelerated by a rising proof, laboratories are adopting digital pathology to boost routine operations, enhance decision-making, and lay the muse for unlocking new insights with AI.
“At QDx Pathology Companies, we’re dedicated to advancing the usual of excellence in pathology,” stated Pierre Mouawad, VP of Laboratory Operations. “Proscia’s software program makes it simpler for our pathologists to do their greatest work, empowering them to optimize for velocity and precision. We have now already seen an affect from our determination to undertake this state-of-the-art answer.”
With its intuitive person expertise, sturdy performance, and scalability, Proscia’s software program allows pathologists to drive productiveness and confidence good points of their routine workflows. This consists of streamlining collaboration, which helps them to faucet right into a broader pool of experience. QDx Pathology Companies plans to keep up its place of innovation by leveraging the answer’s world-class interoperability with AI purposes developed by Proscia, Proscia’s prospects, and the Proscia Prepared companions.
“It’s inspiring to look at QDx Pathology Companies take the primary steps on its digital pathology journey,” stated David West, Proscia’s CEO. “The staff understands all that it takes to achieve success, together with a tradition of innovation, dedication to its pathologists and people impacted by their work, and a powerful software program basis. We have now full confidence that it’s going to notice the complete promise of digital pathology.”
Immediately’s information is the newest in a collection of latest bulletins from Proscia. Final month, the corporate acquired FDA 510(k) clearance for its Concentriq AP-Dx answer. It additionally launched the Proscia Ready partner alliance to assist life sciences organizations and diagnostic laboratories speed up the scaled adoption of digital pathology with confidence.
To be taught extra about Proscia’s software program and see a demo, go to sales space 200 throughout the upcoming United States and Canadian Academy of Pathology (USCAP) 113th Annual Assembly.